T-Cell & NK-Cell Lymphomas
Prognosis
This section is being prepared by our editorial process.
🔬 Histological Types
📚 Latest Research
Integrative pooled transcriptomic analysis reveals shared and distinct molecular signatures in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
Akbarin MM, et al
An integrative pooled transcriptomic analysis of publicly available Gene Expression Omnibus microarray datasets has identified both shared and distinct molecular signatures in adult T-cell leukemia/lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL), two aggressive blood cancers with poor prognosis and limited treatment options. Both malignancies showed upregulation of extracellular matrix (ECM) components — including COL1A1, COL3A1, FN1, SPARC, and THBS1 — along with shared activation of ECM-receptor interaction, focal adhesion, and PI3K-Akt signaling pathways. PTCL was additionally enriched in coagulation and angiogenesis programs, while ATLL displayed distinct activation of cytoskeletal, chemokine, and immune-regulatory pathways. Hub genes such as COL1A1, FN1, and the CXCL12-CXCR4 axis emerge as candidate molecular signatures that may guide future therapeutic strategies, pending validation in independent patient cohorts and functional studies.
Functional & integrative genomics
Source →A systematic review of Human T-cell Lymphotropic Virus type-1 (HTLV-1) seroprevalence worldwide and an update on HTLV-1 diagnoses and associated diseases in England and Wales.
Mughal S, et al
Annual diagnoses of adult T-cell leukaemia/lymphoma (ATLL) are rising in England and Wales, with the incidence rate ratio comparing 2013–2022 to 1993–1997 reaching 1.60 (95% CI 1.17–2.23), in parallel with a near-tripling of the estimated number of people living with HTLV-1 from 11,654 in 1991 to 28,846 in 2021. Among 749 newly diagnosed individuals in 2013–2022, 58% were women, 64% were tested in London, Black Caribbean ethnicity predominated (61% of those with ethnicity recorded), and ATLL was the most common presentation among symptomatic patients (47%, 187/396). These trends highlight an urgent need for enhanced public health interventions — including improved screening and awareness programmes — to address the growing burden of HTLV-1-associated T-cell malignancy in England and Wales.
International journal of STD & AIDS
Source →Anti-CD94 Monoclonal Antibody Dibotatug-Induced Response in a Refractory Primary CNS T-Cell Lymphoma.
Grommes C, et al
A patient with refractory primary CNS T-cell lymphoma achieved a clinical response following treatment with dibotatug, an anti-CD94 monoclonal antibody, marking a notable outcome in a disease with very limited therapeutic options. Primary CNS T-cell lymphoma is an exceptionally rare and aggressive malignancy that typically fails standard immunochemotherapy regimens, leaving patients with a dire prognosis. The anti-CD94 target is expressed on subsets of T cells and NK cells, and this case report published in JCO Precision Oncology suggests that targeting CD94 with dibotatug may represent a viable salvage strategy for this difficult-to-treat entity. These findings support further investigation of anti-CD94 immunotherapy in refractory T-cell lymphomas affecting the central nervous system.
JCO precision oncology
Source →💊 Therapies
🥗 Diet
🫙 Supplements
🧪 Tumor markers
This section is being prepared by our editorial process.
💬 Discussion Forum
🩺 Centers for this diagnosis
Warszawa, PL
OECI OECI treats this diagnosis
Warszawa, PL
treats this diagnosis